北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗55.6856.962.4771.19亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15.5115.201.5956.04亿6山东药玻15.6115.661.79147.65亿7康德莱16.0916.111.3334.68亿8维力医疗 1 ...

新疆电力现货市场运行期间，不再开展与现货市场并行的调峰服务交易。 文 | 国家能源局新疆监管办公室 7月11日，国家能源局新疆监管办公室 印发《新疆电力辅助服务市场实施细则》。本细则中电力辅助服务市场品种包括调峰服务、调频服务、备用 服务。 经营主体包括发电企业、售电企业、电力用户和新型经营主体。新型经营主体： 新疆省调及以上电力调度机构直调，参与疆内电力电量平衡的独立 储能电站。 其中，获得容量电费的经营主体原则上应当参与辅助服务市场申报。逐步推进虚拟电厂、智能微电网、车网互动运营企业等新型经营主体参与辅助 服务市场。 调峰服务市场： 现阶段调峰辅助服务市场包括实时调峰交易、启停调峰交易。当疆内新能源存在弃电情况时，即可启动调峰服务市场。 实时调峰交易 实时调峰交易的辅助服务提供方包括火电机组、 独立储能，辅助服务受益方包括新能源场站、 出力未达到调峰基准的火电机组、发电上网的自备 电厂、放电上网的独立储能。 独立储能： 其中，火电机组应参与实时调峰交易申报， 独立储能自愿 以充电状态参与实时调峰交易。 经营主体参与实时调峰交易， 须能够按照 电力调度机构指令，满足一定调节速率要求，可平 滑稳定地调整出力。 ...

证券代码：300666 证券简称：江丰电子 公告编号：2025-071 宁波江丰电子材料股份有限公司 发行人声明 在虚假记载、误导性陈述或重大遗漏，并对预案的真实性、准确性、完整性承担 个别和连带的法律责任。 法》等要求编制。 行负责；因本次发行引致的投资风险，由投资者自行负责。投资者如有任何疑问， 应咨询自己的股票经纪人、律师、专业会计师或其他专业顾问。 的声明均属不实陈述。 关事项的实质性判断、确认、批准，本预案所述本次发行相关事项的生效和完成 尚待取得有关审批机关的批准或注册。 特别提示 次会议、第四届监事会第十八次会议审议通过，尚需获得公司股东会审议通过、 深交所审核通过并经中国证监会同意注册后方可实施。以上批准或注册均为本次 向特定对象发行 A 股股票的前提条件，能否取得相关的批准或注册，以及最终 取得批准或注册的时间存在不确定性，敬请投资者注意投资风险。 特定投资者，包括符合中国证监会规定的证券投资基金管理公司、证券公司、信 托公司、财务公司、保险机构投资者、合格境外机构投资者、人民币合格境外机 构投资者，以及符合中国证监会规定的其他法人、自然人或其他合格的投资者等。 其中，证券投资基金管理公司、 ...

证券代码：001391 证券简称：国货航 公告编号：2025-044 中国国际货运航空股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 中国国际货运航空股份有限公司（以下简称"国货航" "公司" ）第二届董事会第二次会议（以下简称"本次会议"） 于 2025 年 7 月 10 日以通讯表决方式召开，会议通知已于 公司部分高级管理人员列席本次会议。本次会议的召开符合 《中华人民共和国公司法》等法律法规及《中国国际货运航 空股份有限公司章程》的规定。 二、董事会会议审议情况 本次会议审议并通过了《关于向国航股份购买发动机暨 关联交易的议案》 同意公司与关联方中国国际航空股份有限公司（以下简 称"国航股份" ）签订关联交易协议，向国航股份购置 2 台 Trent772C 备用发动机和 1 台 GTCP331-350C 备用 APU。具体 内容请见公司同日于深圳证券交易所网站（www.szse.cn）及 指定媒体披露的《关于向国航股份购买发动机暨关联交易的 公告》。 三、备查文件 表决结果：10 票同意、0 票反对、0 票弃权。关联 ...

中信证券股份有限公司关于 中国国际货运航空股份有限公司 向中国国际航空股份有限公司购买发动机暨关联交易的核查意见 注册地址 北京市顺义区天柱路 30 号院 1 号楼 1 至 9 层 101 法定代表人 马崇贤 国际、国内定期和不定期航空客、货、邮和行李运输业务；国 内、国际公务飞行业务；飞机执管业务；航空器维修；航空公司 间业务代理。与主营业务有关的地面服务和航空快递（信件和信 件性质的物品除外） 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为中国国 际货运航空股份有限公司（以下简称"国货航"或"公司"）首次公开发行股票 并上市及持续督导的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等有关规定，就国货航拟向中国国际航空股份有限公司（以 下简称"国航股份"）购买发动机暨关联交易的相关事项进行了核查，具体情况 如下： 一、关联交易概述 国货航拟向国航股份购置 2 台 Trent772C 备用发动机和 1 台 GTCP331-350C 备用 APU（以下简称"本次交易"）。 国航股份系公司实际控制 ...

一、停复牌 1、仕佳光子：拟以购买光电子基金、刘晓明等5名交易对方合计持有的福可喜玛82.3810%股权；同时 拟向不超过35名特定投资者发行股份募集配套资金；股票复牌。 2、良品铺子：控股股东宁波汉意正在筹划重大事项，该事项可能导致公司控制权发生变更，股票停 牌。 三、业绩变动 1、国盛金控：预计上半年净利润1.5亿元-2.2亿元，同比增长236.85%-394.05%，经纪业务、投行业务业 绩同比有较好提升。 2、赛力斯：预计上半年净利润为27亿元到32亿元，同比上升66.20%到96.98%，公司二季度销量较一季 度相比有较大幅度的增长。 3、秦安股份：拟通购买亦高光电99%股权并募集配套资金，股票复牌。 二、投资合作、经营状况 1、巨星科技：取得来自某国际大型零售业公司的采购确认，采购标的为20V无绳锂电池电动工具系列 和相关零配件，预计订单整体采购金额为每年不少于3000万美元，超过公司2024年电动工具产品收入的 10%。 2、国星光电：拟定增募资不超过9.8亿元，用于"超高清显示Mini/Micro LED及显示模组产品生产建设 项目"等。 3、江丰电子：拟定增募资不超过19.5亿元，用于年产5 ...

江丰电子（300666）公告，拟定增募资不超过19.48亿元，用于年产5100个集成电路设备用静电吸盘产 业化项目、年产12300个超大规模集成电路用超高纯金属溅射靶材产业化项目、上海江丰电子研发及技 术服务中心项目和补充流动资金及偿还借款。 ...

Core Viewpoint - The article highlights the robust development of the Changsha Economic Development Zone, emphasizing its focus on project construction and investment acceleration to drive high-quality economic growth. Group 1: Project Development - Changsha Economic Development Zone has adopted the philosophy of "projects first" and has initiated a "project construction acceleration year" campaign, holding nearly 30 specialized meetings to address challenges and enhance resource support [1] - The opening rate of key provincial and municipal projects for 2025 has exceeded 76%, with a total investment of 636.9 billion yuan across 39 projects, of which 70.35 billion yuan has been invested in the first half of the year, accounting for 60.6% of the annual plan [1] - Significant projects include the high-efficiency energy-saving intelligent motor project, which will feature a digital smart workshop and 20 intelligent production lines, expected to be operational by March next year [2] Group 2: Investment and Economic Growth - The Changsha Economic Development Zone has introduced 62 new projects with a total investment of 329.6 billion yuan this year, including major projects from companies like Zhongke Shuguang and Zhihui Future [6] - The zone is focusing on both traditional and emerging industries, enhancing existing industrial chains while also developing new ones, with projects like sodium energy and advanced manufacturing being prioritized [8][9] - The zone's efforts in optimizing the business environment have led to it ranking sixth among national economic development zones for convenience in 2024, reflecting its commitment to improving service efficiency for enterprises [10] Group 3: Policy and Support Mechanisms - The Changsha Economic Development Zone has implemented a comprehensive project lifecycle management mechanism to streamline processes from negotiation to project completion, reducing approval times by nearly 40% [11] - The zone has introduced flexible land supply management methods to alleviate financial pressures on enterprises while meeting land needs [12] - Various support measures have been enacted, including simplified approval processes and targeted assistance for enterprises, resulting in the resolution of 200 enterprise requests and the organization of numerous recruitment and financing events [12]

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 18.77 yuan, with a PE ratio of 56.31, marking a new low in 273 days, and a total market capitalization of 7.2 billion yuan [1] - The average PE ratio for the medical device industry is 51.42, with a median of 37.44, placing Chunzhi Medical at the 88th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunzhi Medical, including 8 funds, with a total holding of 31.63 million shares valued at 429 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The latest performance report for the first quarter of 2025 shows that the company achieved revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]

Core Viewpoint - Hualing Cable has significantly expanded its market presence in the power and new energy sectors, securing multiple contracts totaling 4.56 billion yuan, contributing to a cumulative contract amount of 8.79 billion yuan for the year [1][2][3]. Group 1: Contract Wins and Financial Performance - The recent contracts won by Hualing Cable represent approximately 10.97% of the audited revenue for 2024 [2]. - The company reported a 19.82% year-on-year increase in revenue for 2024, reaching 4.158 billion yuan, with net profit and non-recurring net profit growing by 26.07% and 37.73%, respectively [6][7]. - In Q1 2025, Hualing Cable achieved revenue of 1.005 billion yuan, with net profit and non-recurring net profit increasing by 11.38% and 101.34%, respectively [6][7]. Group 2: Market Position and Product Offerings - Hualing Cable specializes in the research, production, and sales of various types of cables, including special cables, power cables, and electrical equipment cables, serving sectors such as aerospace, data communication, and new energy [3][4]. - The company has established long-term partnerships with major state-owned enterprises across various industries, enhancing its market influence and core competitiveness [4]. Group 3: Research and Development - Hualing Cable has increased its R&D investment to 134 million yuan in 2024, marking a 17.03% increase and achieving a historical high [7]. - The company holds 345 authorized patents, including 54 invention patents, reflecting its commitment to innovation and technology development [7]. Group 4: Expansion and Future Plans - Hualing Cable plans to raise up to 1.215 billion yuan through a private placement to fund projects related to new energy and high-end special cables, as well as to enhance its operational capabilities [5]. - The company is also pursuing an acquisition of Hunan Xingxin Aerospace New Materials Co., aiming to strengthen its position in high-end materials, particularly in aerospace applications [7].